Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNA tumor vaccine in KRAS-mutated advanced solid tumors
NCT05202561Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Mar 2022
- Primary completion
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RNA tumor vaccine in solid tumor (advanced stage) (2 arms), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Incidence of adverse events up to 6 months. Status: unknown.
02
Drugs
RNA tumor vaccine
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05202561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202561.